Regeneron Pharmaceuticals Inc (REGN)
Healthcare
Biotechnology
762.60 $
+3.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Regeneron Pharmaceuticals Inc (REGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 94.8% of the shares are freely tradable; institutional investors hold 92.3%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
92.3%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
94.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
3.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
103Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 8.66 | 9,075,153 | +0.3 | 12/31/2025 |
| BlackRock Inc | 8.53 | 8,947,735 | +2.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 6.35 | 6,654,913 | +0.0 | 03/31/2026 |
| State Street Corp | 4.45 | 4,664,478 | +0.1 | 03/31/2026 |
| Dodge & Cox | 4.25 | 4,458,238 | -3.0 | 03/31/2026 |
| JPMorgan Chase & Co | 4.11 | 4,311,806 | +9.4 | 03/31/2026 |
| Franklin Resources Inc | 2.60 | 2,722,071 | +6.3 | 03/31/2026 |
| Geode Capital Management, LLC | 2.49 | 2,607,732 | +3.5 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 3.16 | 3,310,556 | +0.3 | 04/30/2026 |
| Dodge & Cox Stock I | 2.77 | 2,908,804 | -2.9 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.